Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Anti-CD19 CAR-transduced T cells (Primary)
- Indications Acute lymphoblastic leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Beijing Doing Biomedical
- 28 Nov 2017 Planned End Date changed from 1 Apr 2020 to 1 Jun 2020.
- 28 Nov 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Jun 2019.
- 28 Nov 2017 Planned initiation date changed from 1 Oct 2017 to 1 Dec 2017.